These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35927906)

  • 1. Efficacy of Sinopharm Vaccine Among Stem Cell Transplant Recipients During Two Peaks of Delta and Omicron variants of COVID-19.
    Ghasemi A; Khodashahi R; Aliakbarian M; Khaleghi E; Razmkhah B; Vahdatinia M; Far MS; Bakhti O
    Curr Drug Saf; 2023; 18(4):540-546. PubMed ID: 35927906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications and Efficacy of Sinopharm Vaccine among Liver and Kidney Transplantation.
    Aliakbarian M; Khodashahi R; Sabbagh MG; Rezayat KA; Khodashahi M; Khaleghi E; Moghaddam MD; Razmkhah B; Nazar MN; Sheikhi N
    Curr Drug Saf; 2023; 18(1):15-22. PubMed ID: 35249504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of COVID 19 vaccination on kidney recipients.
    Marzieh L; Elahe P; Habib R; Maryam P; Arefeh J; Elnaz E; Sanaz D
    Transpl Immunol; 2022 Oct; 74():101658. PubMed ID: 35777613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
    Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
    Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
    Lauring AS; Tenforde MW; Chappell JD; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Adams K; Schrag SJ; Olson SM; Kobayashi M; Verani JR; Patel MM; Self WH;
    BMJ; 2022 Mar; 376():e069761. PubMed ID: 35264324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks.
    Albreiki M; Mousa M; Azman SK; Vurivi H; Alhalwachi Z; Alshehhi F; AlShamsi S; Marzouqi NA; Alawadi T; Alrand H; Oulhaj A; Fikri A; Alsafar H
    Front Immunol; 2023; 14():1049393. PubMed ID: 36860855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.
    Enayatrad M; Mahdavi S; Aliyari R; Sahab-Negah S; Nili S; Fereidouni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Sharifi H; Emamian MH
    BMC Infect Dis; 2023 Mar; 23(1):150. PubMed ID: 36899326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan.
    Jamal Z; Haider M; Ikram A; Salman M; Rana MS; Rehman Z; Haider SA; Ammar M; Nisar N; Umair M
    Front Public Health; 2022; 10():987452. PubMed ID: 36249252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.
    Karimi M; Zarei T; Haghpanah S; Azarkeivan A; Naderi M; Matin S; Bazrafshan A; Zahedi Z; Shirkavand A; Pishdad P; De Sanctis V
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022026. PubMed ID: 35444764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.